Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Here’s Why

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares gapped up prior to trading on Tuesday . The stock had previously closed at $14.33, but opened at $14.8864. Astellas Pharma shares last traded at $14.43, with a volume of 8,332 shares trading hands.

Analysts Set New Price Targets

Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Astellas Pharma Trading Up 0.4%

The company has a current ratio of 1.17, a quick ratio of 0.90 and a debt-to-equity ratio of 0.17. The company has a market cap of $26.04 billion, a price-to-earnings ratio of 10.95 and a beta of 0.08. The firm has a 50-day moving average price of $13.60 and a 200 day moving average price of $14.65.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).